Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2 (Heliyon, in press)

Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2 (Heliyon, in press)
In collaboration with Osaka University (Profs Masaki Mori and Yuichiro Doki) and Kanazawa University (Prof Noriko Gotoh), Asai et al. demonstrated that methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), an enzyme in one carbon metabolism, played a role in cancer cell metabolism and showed several candidate tool compounds for drug discovery. The findings of the present study will help to develop anticancer drugs targeting MTHFD2, with a view to minimizing the adverse effects of anticancer drugs.

前へ ＜

＞ 次へ

記事一覧に戻る